Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patientsCatherine Patte, Mitchell S. Cairo, Anne Aupérin et al.|Blood|2006Cited by 431
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsMitchell S. Cairo, Catherine Patte, Mary Gerrard et al.|Blood|2006Cited by 362
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B‐cell non‐Hodgkin’s lymphoma: results of the FAB/LMB 96 international study*Mary Gerrard, Catherine Patte, Mitchell S. Cairo et al.|British Journal of Haematology|2008Cited by 201
Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 StudyMitchell S. Cairo, Catherine Patte, Richard Sposto et al.|Journal of Clinical Oncology|2012Cited by 181
Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international studyHélène-Antoine Poirel, Catherine Patte, Mitchell S. Cairo et al.|Leukemia|2008Cited by 134